Figures & data
Table 1. Demographics and selected baseline characteristics of cystic fibrosis patients treated with dornase alfa.
Table 2. Dornase alfa adherence as measured by medication possession ratio in the post-index period.
Table 3. Utilization and healthcare charges in the outcome period, stratified by dornase alfa adherence, in patients with cystic fibrosis.
Pulmozyme®. (dornase alfa) [prescribing information]. South San Francisco, CA: Genentech, Inc., 2010 Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 2007;176:957–69 World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003 O’Malley AS, Pham HH, Schrag D, et al. Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care 2007;45:562–70 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83 Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–82 Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989–96 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9 Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–7